SK Biopharmaceuticals Co Ltd
KRX:326030
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
KR |
|
Gillette India Ltd
NSE:GILLETTE
|
IN |
|
N
|
NMDC Steel Ltd
NSE:NSLNISP
|
IN |
|
G
|
Graubuendner Kantonalbank
SIX:GRKP
|
CH |
|
Prairie Provident Resources Inc
TSX:PPR
|
CA |
|
Achilles Corp
TSE:5142
|
JP |
|
Nuvei Corp
TSX:NVEI
|
CA |
|
P
|
PCTEL Inc
F:PEW
|
US |
|
P
|
Pine Cliff Energy Ltd
TSX:PNE
|
CA |
|
A
|
AmeriGuard Security Services Inc
OTC:AGSS
|
US |
|
D
|
Daeyang Paper MFG Co Ltd
KOSDAQ:006580
|
KR |
|
Freelancer Ltd
ASX:FLN
|
AU |
|
L
|
Lundin Energy AB
XBER:LYV
|
SE |
|
Balyo SA
PAR:BALYO
|
FR |
|
E
|
Eurospan Holdings Bhd
KLSE:EURO
|
MY |
|
P
|
Palfinger AG
VSE:PAL
|
AT |
Wall Street
Price Targets
Price Targets Summary
SK Biopharmaceuticals Co Ltd
According to Wall Street analysts, the average 1-year price target for
SK Biopharmaceuticals Co Ltd
is 144 184.29 KRW
with a low forecast of 73 730 KRW and a high forecast of 173 250 KRW.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SK Biopharmaceuticals Co Ltd's stock price target?
Price Target
144 184.29
KRW
According to Wall Street analysts, the average 1-year price target for
SK Biopharmaceuticals Co Ltd
is 144 184.29 KRW
with a low forecast of 73 730 KRW and a high forecast of 173 250 KRW.
What is SK Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
23%
For the last 7 years the
compound annual growth rate for
SK Biopharmaceuticals Co Ltd's revenue is
152%.
The projected
CAGR
for the next 3 years is
23%.
What is SK Biopharmaceuticals Co Ltd's Operating Income forecast?
Projected CAGR
31%
The
compound annual growth rate
of SK Biopharmaceuticals Co Ltd's operating income for the next 3 years is
31%.
What is SK Biopharmaceuticals Co Ltd's Net Income forecast?
Projected CAGR
17%
The
compound annual growth rate
of SK Biopharmaceuticals Co Ltd's net income for the next 3 years is
17%.
